Exploring the role of MKK7 in excitotoxicity and cerebral ischemia: A novel pharmacological strategy against brain injury

Cell Death and Disease

Volumn 6, Issue , 2015, Pages e1854-

  Vercelli, A ^a,b   Biggi, S ^c   Sclip, A ^c   Repetto, I E ^a   Cimini, S ^c   Falleroni, F ^c   Tomasi, S ^a   Monti, R ^a   Tonna, N ^d   Morelli, F ^c   Grande, V ^a,c   Stravalaci, M ^c   Biasini, E ^c   Marin, O ^e   Bianco, F ^d,f   Di Marino, D ^g,h   Borsello, T ^c,i  

^a UNIVERSITY OF TURIN   (Italy)

^b National Institute of Neuroscience   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d Sanipedia Srl   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

^f Neuroinflammation Lab   (Italy)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

^h CITY UNIVERSITY OF NEW YORK   (United States)

ⁱ UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PENETRATING PEPTIDE; GLUCOSE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45BETA INHIBITOR PEPTIDE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID; NEUROPROTECTIVE AGENT; OXYGEN; STRESS ACTIVATED PROTEIN KINASE; SYNTHETIC PEPTIDE; TAT GROWTH ARREST AND DNA DAMAGE INDUCIBLE 45BETA 69 86 PEPTIDE; TAT SPACER GROWTH ARREST AND DNA DAMAGE INDUCIBLE 45BETA 60 86 PEPTIDE; UNCLASSIFIED DRUG; DIFFERENTIATION ANTIGEN; GADD45B PROTEIN, MOUSE; MAP2K7 PROTEIN, MOUSE; N METHYLASPARTIC ACID; PEPTIDE;

ADULT; AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN CELL CULTURE; BRAIN DAMAGE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; BRAIN SIZE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENCY; DRUG SPECIFICITY; DRUG TARGETING; ELECTROCOAGULATION; ENZYME ACTIVATION; EXCITOTOXICITY; EXPERIMENTAL BRAIN INJURY; EXPERIMENTAL CEREBRAL ISCHEMIA; IN VITRO STUDY; IN VIVO STUDY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; THERAPEUTIC INDEX; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN CORTEX; CELL HYPOXIA; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; INFARCTION, MIDDLE CEREBRAL ARTERY; METABOLISM; MOLECULAR DOCKING; MOLECULAR GENETICS; NERVE CELL; NEWBORN; PATHOLOGY; PRIMARY CELL CULTURE; PROTEIN ENGINEERING; SPRAGUE DAWLEY RAT; SYNTHESIS; THROMBOEMBOLISM; TISSUE CULTURE TECHNIQUE;

AMINO ACID SEQUENCE; ANIMALS; ANIMALS, NEWBORN; ANTIGENS, DIFFERENTIATION; CELL HYPOXIA; CEREBRAL CORTEX; ELECTROCOAGULATION; GENE EXPRESSION REGULATION; GLUCOSE; INFARCTION, MIDDLE CEREBRAL ARTERY; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MAP KINASE KINASE 7; MOLECULAR DOCKING SIMULATION; MOLECULAR SEQUENCE DATA; N-METHYLASPARTATE; NEURONS; NEUROPROTECTIVE AGENTS; PEPTIDES; PRIMARY CELL CULTURE; PROTEIN ENGINEERING; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; THROMBOEMBOLISM; TISSUE CULTURE TECHNIQUES;

EID: 84961939465     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2015.226     Document Type: Article

References (56)

1. Lipton SA. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov 2006;5:160-170.
2. Borsello T, Clarke PG, Hirt L, Vercelli A, Repici M, Schorderet DF et al. A peptide inhibitor of c-Jun. N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat Med 2003;9:1180-1186.
3. Centeno C, Repici M, Chatton JY, Riederer BM, Bonny C, Nicod P et al. Role of the JNK pathway in NMDA-mediated excitotoxicity of cortical neurons. Cell Death Differ 2007;14:240-253.
4. Repici M, Centeno C, Tomasi S, Forloni G, Bonny C, Vercelli A et al. Time-course of c-Jun. N-terminal kinase activation after cerebral ischemia and effect of D-JNKI1 on c-Jun. and caspase-3 activation2007 Neuroscience 150:40-49.
5. Repici M, Mare L, Colombo A, Ploia C, Sclip A, Bonny C et al. c-Jun. N-terminal kinase binding domain-dependent phosphorylation of mitogen-activated protein kinase kinase 4 and mitogen-activated protein kinase kinase 7 and balancing cross-talk between c-Jun. N-terminal kinase and extracellular signal-regulated kinase pathways in cortical neurons. Neuroscience 2009;159:94-103.
6. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000;103:239-252.
7. Matsuoka M, Igisu H, Nakagawa K, Katada T, Nishina H. Requirement of MKK4 and MKK7 for CdCl2- or HgCl2-induced activation of c-Jun. NH2-terminal kinase in mouse embryonic stem cells. Toxicol Lett 2004;152:175-181.
8. Harper SJ, LoGrasso P. Signalling for survival and death in neurones: the role of stressactivated kinases, JNK and p38. Cell Signal 2001;13:299-310.
9. Papa S, Zazzeroni F, Bubici C, Jayawardena S, Alvarez K, Matsuda S et al. Gadd45 beta mediates the NF-kappa B suppression of JNK signalling by targeting MKK7/JNKK2. Nat Cell Biol 2004;6:146-153.
10. Zhou G, Golden T, Aragon IV, Honkanen RE. Ser/Thr protein phosphatase 5 inactivates hypoxia-induced activation of an apoptosis signal-regulating kinase 1/MKK-4/JNK signaling cascade. J Biol Chem 2004;279:46595-46605.
11. Borsello T, Croquelois K, Hornung JP, Clarke PG. N-methyl-d-aspartate-triggered neuronal death in organotypic hippocampal cultures is endocytic, autophagic and mediated by the c-Jun. N-terminal kinase pathway. Eur J Neurosci 2003;18:473-485.
12. Hirt L, Badaut J, Thevenet J, Granziera C, Regli L, Maurer F et al. D-JNKI1, a cell-penetrating c-Jun-N-terminal kinase inhibitor, protects against cell death in severe cerebral ischemia. Stroke 2004;35:1738-1743.
13. Davies C, Tournier C. Exploring the function of the JNK (c-Jun. N-terminal kinase) signalling pathway in physiological and pathological processes to design novel therapeutic strategies. Biochem Soc Trans 2012;40:85-89.
14. Tornatore L, Marasco D, Dathan N, Vitale RM, Benedetti E, Papa S et al. Gadd45 beta forms a homodimeric complex that binds tightly to MKK7. J Mol Biol 2008;378:97-111.
15. Papa S, Monti SM, Vitale RM, Bubici C, Jayawardena S, Alvarez K et al. Insights into the structural basis of the GADD45beta-mediated inactivation of the JNK kinase, MKK7/JNKK2. J Biol Chem 2007;282:19029-19041.
16. Tian J, Locker J. Gadd45 in the liver: signal transduction and transcriptional mechanisms. Adv Exp Med Biol 2013;793:69-80.
17. Borsello T, Bonny C. Use of cell-permeable peptides to prevent neuronal degeneration. Trends Mol Med 2004;10:239-244.
18. Yamasaki T, Kawasaki H, Arakawa S, Shimizu K, Shimizu S, Reiner O et al. Stress-activated protein kinase MKK7 regulates axon elongation in the developing cerebral cortex. J Neurosci 2011;31:16872-16883.
19. Wang X, Nadarajah B, Robinson AC, McColl BW, Jin JW, Dajas-Bailador F et al. Targeted deletion of the mitogen-activated protein kinase kinase 4 gene in the nervous system causes severe brain developmental defects and premature death. Mol Cell Biol 2007;27:7935-7946.
20. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-1587.
21. Cronin CA. Intravenous tissue plasminogen activator for stroke: a review of the ECASS III results in relation to prior clinical trials. J Emerg Med 2010;38:99-105.
22. Wang W, Li M, Chen Q, Wang J. Hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke: mechanisms, models, and biomarkers. Mol Neurobiol 2014.
23. Wardlaw JM, Sandercock PA, Berge E. Thrombolytic therapy with recombinant tissue plasminogen activator for acute ischemic stroke: where do we go from here? A cumulative meta-analysis. Stroke 2003;34:1437-1442.
24. Kleindorfer D, Lindsell CJ, Brass L, Koroshetz W, Broderick JP. National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate. Stroke 2008;39:924-928.
25. Stankowski JN, Gupta R. Therapeutic targets for neuroprotection in acute ischemic stroke: lost in translation? Antioxid Redox Signal 2011;14:1841-1851.
26. Yuan J. Neuroprotective strategies targeting apoptotic and necrotic cell death for stroke. Apoptosis 2009;14:469-477.
27. Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 2009;40:2244-2250.
28. Schmidt A, Minnerup J, Kleinschnitz C. Emerging neuroprotective drugs for the treatment of acute ischaemic stroke. Expert Opin Emerg Drugs 2013;18:109-120.
29. Puyal J, Ginet V, Clarke PG. Multiple interacting cell death mechanisms in the mediation of excitotoxicity and ischemic brain damage: a challenge for neuroprotection. Prog Neurobiol 2013;105:24-48.
30. Lai TW, Zhang S, Wang YT. Excitotoxicity and stroke: identifying novel targets for neuroprotection. Prog Neurobiol 2014;115:157-188.
31. Chen M, Lu TJ, Chen XJ, Zhou Y, Chen Q, Feng XY et al. Differential roles of NMDA receptor subtypes in ischemic neuronal cell death and ischemic tolerance. Stroke 2008;39:3042-3048.
32. Jo H, Mondal S, Tan D, Nagata E, Takizawa S, Sharma AK et al. Small molecule-induced cytosolic activation of protein kinase Akt rescues ischemia-elicited neuronal death. Proc Natl Acad Sci USA 2012;109:10581-10586.
33. Zhang S, Taghibiglou C, Girling K, Dong Z, Lin SZ, Lee W et al. Critical role of increased PTEN nuclear translocation in excitotoxic and ischemic neuronal injuries. J Neurosci 2013;33:7997-8008.
34. Aarts M, Liu Y, Liu L, Besshoh S, Arundine M, Gurd JW et al. Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions. Science 2002;298:846-850.
35. Cook DJ, Teves L, Tymianski M. Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain. Nature 2012;483:213-217.
36. Cook DJ, Teves L, Tymianski M. A translational paradigm for the preclinical evaluation of the stroke neuroprotectant Tat-NR2B9c in gyrencephalic nonhuman primates. Sci Transl Med 2012;4:154ra133.
37. Christopherson KS, Hillier BJ, Lim WA, Bredt DS. PSD-95 assembles a ternary complex with the N-methyl-D-aspartic acid receptor and a bivalent neuronal NO synthase PDZ domain. J Biol Chem 1999;274:27467-27473.
38. Sattler R, Xiong Z, Lu WY, Hafner M, MacDonald JF, Tymianski M. Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science 1999;284:1845-1848.
39. Tomasi S, Sarmientos P, Giorda G, Gurewich V, Vercelli A. Mutant prourokinase with adjunctive C1-inhibitor is an effective and safer alternative to tPA in rat stroke. PLoS One 2011;6:e21999.
40. Stetler RA, Leak RK, Gan Y, Li P, Zhang F, Hu X et al. Preconditioning provides neuroprotection in models of CNS disease: paradigms and clinical significance. Prog Neurobiol 2014;114:58-83.
41. Queiroga CS, Tomasi S, Wideroe M, Alves PM, Vercelli A, Vieira HL. Preconditioning triggered by carbon monoxide (CO) provides neuronal protection following perinatal hypoxiaischemia. PLoS One 2012;7:e42632.
42. Liu X, Ye R, Yan T, Yu SP, Wei L, Xu G et al. Cell based therapies for ischemic stroke: from basic science to bedside. Prog Neurobiol 2014;115:92-115.
43. Haeusgen W, Herdegen T, Waetzig V. The bottleneck of JNK signaling: molecular and functional characteristics of MKK4 and MKK7. Eur J Cell Biol 2011;90:536-544.
44. Sanchez R, Pantoja-Uceda D, Prieto J, Diercks T, Marcaida MJ, Montoya G et al. Solution structure of human growth arrest and DNA damage 45alpha (Gadd45alpha) and its interactions with proliferating cell nuclear antigen (PCNA) and Aurora A kinase. J Biol Chem 2010;285:22196-22201.
45. Evans SE, Williams C, Arthur CJ, Poskoñ E, Wattana-Amorn P, Cox RJ et al. Probing the Interactions of early polyketide intermediates with the Actinorhodin ACP from S. coelicolor A3 (2). J Mol Biol 2009;389:511-528.
46. Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 1997;18:2714-2723.
47. De Vries SJ, Van Dijk M, Bonvin AM. The HADDOCK web server for data-driven biomolecular docking. Nat Protoc 2010;5:883-897.
48. Fields GB, Noble RL. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int J Pept Protein Res 1990;35:161-214.
49. Carpino LA, Henklein P, Foxman BM, Abdelmoty I, Costisella B, Wray V et al. The solid state and solution structure of HAPyU. J Org Chem 2001;66:5245-5247.
50. Renolleau S, Aggoun-Zouaoui D, Ben-Ari Y, Charriaut-Marlangue C. A model of transient unilateral focal ischemia with reperfusion in the P7 neonatal rat: morphological changes indicative of apoptosis. Stroke 1998;29:1454-1460; discussion 1461.
51. Busch E, Krüger K, Hossmann KA. Improved model of thromboembolic stroke and rt-PA induced reperfusion in the rat. Brain Res 1997;778:16-24.
52. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989;20:84-91.
53. Belayev L, Alonso OF, Busto R, Zhao W, Ginsberg MD. Middle cerebral artery occlusion in the rat by intraluminal suture. Neurological and pathological evaluation of an improved model. Stroke 1996;27:1616-1622; discussion 1623.
54. Clark WM, Lessov NS, Dixon MP, Eckenstein F. Monofilament intraluminal middle cerebral artery occlusion in the mouse. Neurol Res 1997;19 p 641-648.
55. Bederson JB, Pitts LH, Germano SM, Nishimura MC, Davis RL, Bartkowski HM. Evaluation of 2, 3, 5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke 1986;17:1304-1308.
56. Dohare P, Garg P, Jain V, Nath C, Ray M. Dose dependence and therapeutic window for the neuroprotective effects of curcumin in thromboembolic model of rat. Behav Brain Res 2008;193 p 289-297.